CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer

被引:30
|
作者
Lei, Ningjing
Peng, Bo
Zhang, Jian-Ying [1 ]
机构
[1] Univ Texas El Paso, Dept Biol Sci, El Paso, TX 79968 USA
基金
美国国家卫生研究院;
关键词
CIP2A; cell proliferation; lung cancer; AKT signaling pathway; TRANSFORMATION; EXPRESSION; CARCINOMA; THERAPY; PP2A;
D O I
10.3892/or.2014.3375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancerous inhibitor of PP2A (CIP2A) is an intracellular endogenous protein phosphatase 2A (PP2A) inhibitor with oncogenic activities. Initially identified as a tumor-associated antigen (TAA) in gastric and liver cancer patients, CIP2A was overexpressed in a variety of cancer types. The overexpression of CIP2A in cancer cells is associated with increased cell proliferation. However, the mechanism of CIP2A in cancer cell proliferation remains poorly understood. In the present study, we reported that CIP2A can regulate AKT phosphorylation at S473 under growth factor stimulation and our results also showed that CIP2A may promote cell proliferation through the AKT signaling pathway. Notably, depletion of CIP2A did not induce a global change of AKT phosphatase activity, which indicated that CIP2A may recognize specific AKT targets and play certain roles in the signaling pathway. In addition, we detected that CIP2A expression was associated with mTOR phosphorylation. Our further analysis corroborated the relationship between CIP2A and AKT-mTOR signaling pathway. Therefore, our study addressed a novel role of CIP2A in mediating cancer progression through interacting with the AKT-mTOR signaling pathway.
引用
下载
收藏
页码:1689 / 1694
页数:6
相关论文
共 50 条
  • [1] CIP2A regulates cell proliferation via akt signaling pathway in human lung cancer
    Lei, Ningjing
    Peng, Bo
    Zhang, Jiangying
    CANCER RESEARCH, 2014, 74 (19)
  • [2] CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis
    Fang, Yuanyuan
    Li, Zhengtao
    Wang, Xiuxia
    Zhang, Shulan
    TUMOR BIOLOGY, 2012, 33 (06) : 2299 - 2306
  • [3] CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion
    Zhai, Mo
    Cong, Lin
    Han, Yaxin
    Tu, Guanjun
    TUMOR BIOLOGY, 2014, 35 (02) : 1123 - 1128
  • [4] CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer
    Bo Peng
    Yurong Chai
    Yang Li
    Xinxin Liu
    Jianying Zhang
    BMC Cancer, 15
  • [5] CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer
    Peng, Bo
    Chai, Yurong
    Li, Yang
    Liu, Xinxin
    Zhang, Jianying
    BMC CANCER, 2015, 15
  • [6] CIP2A is overexpressed in human endometrioid adenocarcinoma and regulates cell proliferation, invasion and apoptosis
    Yu, Ning
    Zhang, TingGuo
    Zhao, DaHua
    Cao, Zhang
    Du, Jing
    Zhang, Qian
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (02) : 233 - 239
  • [7] CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer
    Peng, Bo
    Lei, Ningjing
    Chai, Yurong
    Chan, Edward K. L.
    Zhang, Jian-Ying
    MOLECULAR BIOSYSTEMS, 2015, 11 (01) : 105 - 114
  • [8] Helicobacter pylori enhances CIP2A expression and cell proliferation via JNK2/ATF2 signaling in human gastric cancer cells
    Zhao, Yongxun
    Li, Yumin
    Han, Jian
    Liu, Tao
    Guan, Quanlin
    Zhao, Peng
    Guo, Lingyun
    Liu, Kaikun
    He, Dongqiang
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 33 (03) : 703 - 710
  • [9] MTHFD2 facilitates breast cancer cell proliferation via the AKT signaling pathway
    Huang, Jun
    Qin, Yinyin
    Lin, Canfeng
    Huang, Xiaoguang
    Zhang, Feiran
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (01)
  • [10] CIP2A regulates proliferation and apoptosis of multiple myeloma cells
    Zheng, Zhuanzhen
    Qiao, Zhenhua
    Chen, Wenliang
    Gong, Rong
    Wang, Yalin
    Xu, Lianrong
    Ma, Yanping
    Zhang, Li
    Lu, Yujin
    Jiang, Bo
    Li, Guoxia
    Dong, Chunxia
    MOLECULAR MEDICINE REPORTS, 2016, 14 (03) : 2705 - 2709